Owlet, Inc. filings document regulatory disclosures for a public pediatric health technology company whose Class A common stock trades on the New York Stock Exchange under OWLT. Recent Form 8-K reports cover operating results, business updates, executive leadership changes, annual meeting matters and stockholder approval of amendments to the company's equity incentive plan.
The filing record also includes disclosures tied to capital structure and financing activity, including preliminary financial information related to an offering and borrowings under an asset-based revolving credit facility. Other material-event filings document shareholder derivative litigation settlement notices, exchange-listed securities, governance matters and exhibits furnished with earnings releases.
Owlet, Inc. has registered up to 5,346,194 shares of Class A common stock for resale by existing securityholders. These shares were issued to certain investors in exchange for previously outstanding Series A and Series B warrants under an Exchange Agreement dated August 7, 2025. Owlet will not receive any cash from the resale of these shares; any proceeds will go to the selling stockholders, who will also bear any underwriting discounts and selling commissions.
The exchanged shares are subject to a contractual lockup that generally prevents sales or transfers until April 8, 2026, limiting near-term resale activity. The prospectus also explains Owlet’s capital structure, including authorized common and preferred stock, the terms of its Series A and Series B convertible preferred shares, and governance and anti-takeover provisions that shape voting power, director elections, and potential change-of-control transactions.
Owlet, Inc. has filed a registration statement covering the resale of up to 5,346,194 shares of its Class A common stock by existing securityholders. These shares were issued in exchange for certain Series A and Series B warrants under an August 7, 2025 Exchange Agreement, simplifying the company’s capital structure by replacing warrants with stock.
The company will not receive any proceeds from sales of these shares; all sale proceeds will go to the selling stockholders, who will bear any underwriting discounts and selling commissions, while Owlet covers registration expenses. The registered shares are subject to a contractual lockup that generally restricts sales until April 8, 2026. Owlet’s common stock trades on the NYSE under the symbol “OWLT”, with a last reported price of $11.96 per share on November 20, 2025.
Owlet, Inc. filed a Form S-8 to register 375,000 shares of Class A common stock issuable under its 2021 Incentive Award Plan, as Amended.
The filing relies on General Instruction E to incorporate prior effective S-8 registrations for the plan and includes customary exhibits such as a legal opinion and auditor consent.
Owlet, Inc. filed its Q3 2025 10‑Q reporting stronger top‑line and improved profitability. Revenue reached $31,988 thousand versus $22,122 thousand a year ago, lifting gross profit to $16,200 thousand. Operating income was $1,216 thousand, compared with a loss last year, and net income totaled $4,134 thousand, aided by a common stock warrant liability adjustment.
Cash and cash equivalents were $23,760 thousand. The company reported $18,616 thousand outstanding under its asset‑based line of credit and $7,500 thousand drawn on its WTI term loan. Total liabilities were $113,464 thousand and stockholders’ deficit was $54,143 thousand as of September 30, 2025. As a subsequent event, the company completed an offering of 4,825,400 shares at $7.15 per share, yielding net proceeds of $32,109 thousand. Shares outstanding were 27,580,607 as of November 10, 2025.
The filing states conditions that raise substantial doubt about the company’s ability to continue as a going concern, despite a profitable quarter and the October equity raise.
Owlet, Inc. (OWLT) furnished a press release announcing its financial results for the three months ended September 30, 2025 and noting related management changes. The company provided the release as Exhibit 99.1 to a Form 8-K.
The information was furnished under Item 2.02 and, as stated, is not deemed “filed” under the Exchange Act. The filing also lists the cover page Inline XBRL data as Exhibit 104. Owlet’s Class A common stock trades on the NYSE under the symbol OWLT, and the company is identified as an emerging growth company.
Owlet, Inc. launched an underwritten public offering of 4,196,000 shares of Class A common stock at $7.15 per share, with a 30‑day option for underwriters to purchase up to 629,400 additional shares. The company said it intends to use the net proceeds to support continued commercialization, research and development, and for general corporate purposes. Directors, executive officers, and certain stockholders agreed to a 90‑day lock‑up after the date of the final prospectus.
Owlet also provided preliminary unaudited third‑quarter 2025 results: revenue is estimated at $30 million to $32 million, up from $22.1 million a year ago. Estimated gross margin is approximately 49.5%–51% versus 52.2% in the prior‑year period, which the company believes reflects tariff impacts on cost of goods sold. Cash and cash equivalents were approximately $23.8 million as of September 30, 2025 and include about $18.6 million in additional borrowings during the quarter under its asset‑based revolving credit facility.
Owlet, Inc. is offering 4,196,000 shares of Class A common stock at $7.15 per share. The deal implies a gross offering size of $30,001,400, with underwriting discounts of $1,950,091 and estimated net proceeds of $27.4 million after expenses. The underwriters have a 30‑day option to purchase up to 629,400 additional shares. Shares are expected to be delivered on or about October 23, 2025.
Owlet’s stock trades on the NYSE as “OWLT.” The company plans to use proceeds to support continued commercialization, research and development, and general corporate purposes. After the offering, common stock outstanding would be 25,880,584 shares (or 26,509,984 if the option is exercised in full). The filing notes an immediate dilution to new investors of $5.91 per share.
Recent developments include the issuance of 5,426,429 shares in a warrant exchange with a 180‑day lockup, and preliminary Q3 2025 results: revenue estimated at $30–$32 million (vs. $22.1 million a year ago), gross margin of approximately 49.5%–51% (vs. 52.2%), and cash and equivalents of $23.8 million including $18.6 million in additional revolver borrowings.
Owlet, Inc. (OWLT) launched a primary offering of Class A common stock via a preliminary prospectus supplement on the NYSE. The company plans to grant underwriters a 30‑day option to purchase additional shares, with proceeds to support continued commercialization, research and development, and general corporate purposes.
Owlet reported preliminary Q3 2025 results: revenue of $30–$32 million versus $22.1 million a year ago; gross margin of 49.5%–51% versus 52.2% last year, reflecting tariff impacts on cost of goods sold; and cash and cash equivalents of $23.8 million, including $18.6 million of additional borrowings under its asset‑based revolver. On October 10, 2025, the company issued 5,426,429 shares in a warrant exchange, subject to a 180‑day lockup.
Shares outstanding were 16,258,155 as of June 30, 2025, after giving effect to the warrant exchange. The stock last closed at $8.80 on October 20, 2025.
Owlet, Inc. (OWLT) reported an insider ownership change. On 10/10/2025, a director exchanged 131,195 warrants for 80,235 shares of Class A common stock at a ratio of approximately 0.61 shares per warrant (Transaction Codes: A for shares acquired, D for warrants disposed).
The warrants were initially issued in February 2023 in connection with the Company’s Series A Convertible Preferred Stock. Following the transaction, the director beneficially owns 419,004 shares directly and holds 0 warrants. The warrants carried a $4.44 exercise price; the filing lists a $0 price for the derivative security exchange.
Owlet, Inc. (OWLT): Director Form 4 filing — On 10/10/2025, a director acquired 107,626 shares of Class A common stock. Following the transaction, the director beneficially owns 233,030 shares, held directly.
The shares were issued in exchange for previously held warrants tied to the company’s Series A (February 2023) and Series B (February 2024) preferred financings, at approximate exchange ratios of 0.61 and 0.56 shares per warrant. Two warrant positions for 131,195 and 48,621 underlying shares were disposed, leaving zero derivative securities.